2014 Archived Content

Cambridge Healthtech Institute's Third Annual
Point-of-Care Diagnostics
Enabling Personalized Healthcare Through Rapid Diagnostics
Part of the 21st Annual Molecular Medicine Tri-Conference

February 13-14, 2014 | Westin St. Francis | San Francisco, CA


Cambridge Healthtech Institute's Third Annual Point-of-Care Diagnostics symposium will provide an overview of the point-of-care testing landscape with a focus on considerations for test development and commercialization. Point-of-care test developers and end users will address barriers to implementation and present solutions to encourage adoption. Strategies for getting a diagnostic to market as well as for reimbursement and regulatory approval will be discussed. Finally, innovative point-of-care and mobile health technologies will be presented to showcase the latest tools and provide insights into the future of the field.

Day 1 | Day 2Symposia Brochure | Full Event Brochure   

Thursday, February 13

7:30 am Registration and Morning Coffee


POINT-OF-CARE ADOPTION: WHAT WILL IT TAKE?

9:00 Chairperson’s Opening Remarks

Katherine Tynan, Ph.D., President, Tynan Consulting

9:05 Establish Partnership between Laboratory and Healthcare Providers to Improve Clinical Utility of Point-of-Care Testing

Elsie Yu, Ph.D., DABCC, FACB, Director, Toxicology and Point-of-Care Testing; Associate Director, Chemistry, Department of Laboratory Medicine, Geisinger Health System

Although the cost of point-of-care testing is usually higher than in-lab tests, its ability to give immediate test results makes it appealing to many healthcare providers. Close partnership between laboratory and healthcare providers can ensure proper utilization of point-of-care testing and improve patient care. One must also take into consideration regulatory requirements, operational challenges and implementation strategy to make the best out of these bedside testing devices.

9:35 Point-of-Care Testing Device Design: Practical Tips from the User Perspective

Valerie Ng, M.D., Ph.D., Chair, Laboratory Medicine & Pathology, Alameda Heath System/Highland General Hospital

This presentation will discuss known user point-of-care test performance errors and provide suggestions from the user perspective for device design. Relevant regulatory concerns will be included.

10:05 Implementation of Point-of-Care Testing Programs in Community Pharmacies

Donald Klepser, Ph.D., MBA, Assistant Professor, Pharmacy, University of Nebraska Medical Center College of Pharmacy

As economic pressures mount in healthcare, pharmacists are being placed on the frontline. Development of point-of-care diagnostic tests enable pharmacists to assist with patient management and provide cost-effective care. Health policy makers, pharmacy organizations, and governmental agencies have recognized the potential value of placing point-of-care diagnostic in community pharmacies. This presentation will discuss practical aspects of implementing point-of-care testing in pharmacies.

10:35 Coffee Break with Exhibit and Poster Viewing


THE ROLE OF POC IN
COMPANION DIAGNOSTICS

11:05 Why Point-of-Care Technology is Vital for Companion Diagnostics

Peter Miller, COO, Genomic Healthcare Strategies

This presentation will discuss the compelling business reasons for pharma to embrace POC. Selling diagnostics, especially those linked to their drugs, is a new challenge for pharma which has not been fully explored. The old models of pharma selling drugs and reference labs selling tests will change. POC technology will be a critical part of pharma business strategy and offers the opportunity for pharma to better manage the use and profitability of its drugs.

11:35 Use of POC in Oncology Outpatient Practices

Richard A. White, Ph.D., Director, Global Strategy, Breast and Colon Products, Genomic Health, Inc.

With the increased cost of treatment of patients in inpatient settings, economic pressure mounts to reduce overall cost of hospitalization for both acute and chronic treatment. Advances in treatment and diagnostic options have uncovered an opportunity for near-patient testing platforms to serve diagnostic and monitoring purposes.

12:05 pm Sponsored Presentations (Opportunities Available) 

12:35 Luncheon Presentation (Sponsorship Opportunity Available) or Lunch on Your Own

1:05 Session Break


STRATEGIES FOR COMMERCIALIZING
NEW TECHNOLOGIES

1:50 Chairperson’s Remarks

Keith Batchelder, M.D., Founder & CEO, Genomic Healthcare Strategies

1:55 The Role of Evidence-Based Medicine in the Adoption of New POC Technologies

Katherine Tynan, Ph.D., President, Tynan Consulting

Realizing the potential of rapid POC devices to transform the practice of medicine and thereby improve patient outcomes and healthcare cost-effectiveness will be challenging due to misaligned stakeholder interests and the difficulty of changing established medical practice and business models. These barriers, as well as the different stakeholder perspectives, the levels of evidence that can be generated for rapid POC devices and how they can drive change in the healthcare system will be discussed in this presentation.

2:25 Identifying Competitive Advantages for Novel Platform Technologies in Clinical Markets

Rahul Dhanda, Vice President, Marketing, T2 Biosystems

Commercializing new diagnostic platforms requires a clear understanding of the clinical and economic value delivered by the technology, while mapping those advantages to a specific and valuable set of diseases and markets. T2 Biosystems’ T2MR technology provides highly sensitive and rapid results in unprocessed samples and up to 25 times faster than gold standard methods. These advances can be applied to multiple diagnostic markets, including sepsis and hemostasis, which provide a case study for commercializing novel platforms.

2:55 Refreshment Break with Exhibit and Poster Viewing

3:25 PANEL DISCUSSION: Making Your Offering and Getting to Market

Moderator: Keith Batchelder, M.D., Founder & CEO, Genomic Healthcare Strategies

Panelists: Robert Di Tullio, President, Di Tullio Consulting, Inc.

Rahul Dhanda, Vice President, Marketing, T2 Biosystems

Sailesh Chutani, Ph.D., CEO, Mobisante

Matthew Diamond, M.D., Ph.D., Medical Lead, Misfit Wearables

4:25 Breakout Discussions

These interactive discussion groups are open to all attendees, speakers, sponsors, & exhibitors. Participants choose a specific breakout discussion group to join. Each group has a moderator to ensure focused discussions around key issues within the topic. This format allows participants to meet potential collaborators, share examples from their work, vet ideas with peers, and be part of a group problem-solving endeavor. The discussions provide an informal exchange of ideas and are not meant to be a corporate or specific product discussion.

POC Test Design

Moderator: Valerie Ng, M.D., Ph.D., Chair, Laboratory Medicine & Pathology, Alameda Heath System/Highland General Hospital

  • Common point-of-care test performance errors
  • Designing a user-friendly device
  • Regulatory considerations

POC in Global Health

Moderator: Samuel K. Sia, Associate Professor, Biomedical Engineering, Columbia University

  • Partnering with industry, public health, and local governments
  • Developing diagnostics for a specific market
  • Business model options
  • Advances enabling diagnostics in resource-limited settings

Getting your Device to Market

Moderator: Rahul Dhanda, Vice President, Marketing, T2 Biosystems

  • Understanding the clinical and economic value of the technology
  • Mapping tech advantages to a specific set of diseases and markets
  • Commercialization best practices

5:25 Close of Day


Day 1 | Day 2Symposia Brochure | Full Event Brochure    

Japan-Flag Korea-Flag China-Simplified-Flag China-Traditional-Flag 

 

2015 Brochure cover 

Premier Sponsors:

Abbott Molecular 

 

Elsevier  


Jackson Laboratory - small logo 

Leica Biosystems 
 

 NanoString2   

 

Silicon Biosystems 

 

Singulex 

Thomson Reuters-Large